Insider Transactions in Q1 2024 at Travere Therapeutics, Inc. (TVTX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,818
-5.11%
|
$30,544
$8.53 P/Share
|
|
Feb 01
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,174
-3.61%
|
$17,392
$8.53 P/Share
|
|
Feb 01
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
4,195
-4.05%
|
$33,560
$8.53 P/Share
|
|
Feb 01
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
4,764
-2.98%
|
$38,112
$8.7 P/Share
|
|
Feb 01
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
2,820
-5.14%
|
$22,560
$8.53 P/Share
|
|
Feb 01
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
4,764
-2.83%
|
$38,112
$8.7 P/Share
|
|
Feb 01
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
19,122
-2.62%
|
$152,976
$8.7 P/Share
|
|
Jan 31
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+25.07%
|
-
|
|
Jan 31
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+29.33%
|
-
|
|
Jan 31
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+19.43%
|
-
|
|
Jan 31
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+23.58%
|
-
|
|
Jan 31
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,500
+10.32%
|
-
|
|
Jan 31
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+22.63%
|
-
|
|
Jan 31
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+26.75%
|
-
|
|
Jan 23
2024
|
Peter Heerma CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,559
-1.94%
|
$14,031
$9.07 P/Share
|
|
Jan 23
2024
|
Sandra Calvin SVP, CHIEF ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
910
-2.15%
|
$8,190
$9.07 P/Share
|
|
Jan 23
2024
|
William E. Rote SENIOR VICE PRESIDENT, R&D |
SELL
Open market or private sale
|
Direct |
2,062
-3.3%
|
$16,496
$8.96 P/Share
|
|
Jan 23
2024
|
Christopher R. Cline CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
853
-1.69%
|
$7,677
$9.07 P/Share
|
|
Jan 23
2024
|
Eric M Dube CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
7,873
-3.25%
|
$62,984
$8.96 P/Share
|
|
Jan 23
2024
|
Elizabeth E Reed SVP, GC & CORPORATE SECRETARY |
SELL
Open market or private sale
|
Direct |
2,062
-3.55%
|
$16,496
$8.96 P/Share
|
|
Jan 04
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
440
-1.23%
|
$3,960
$9.17 P/Share
|
|
Jan 03
2024
|
Jula Inrig CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,069
-5.48%
|
$18,621
$9.48 P/Share
|